Haematologica, Vol 92, Issue 9, 1246-1249 doi:10.3324/haematol.11319
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, Y.
Right arrow Articles by Zhou, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Y.
Right arrow Articles by Zhou, L.

Multiple Myeloma

Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma

Yonghua Li, Jian Hou, Hua Jiang, Dongxing Wang, Weijun Fu, Zhengang Yuan, Yubao Chen, Lili Zhou

All authors from department of Hematology, Changzheng Hospital, the second hospital affiliated to the Second Military Medical University, 415 Fengyang Rd., Shanghai 200003, PR China

Correspondence: Jian Hou, Department of Hematology, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Rd., Shanghai 200003, PR China. E-mail: houjian167{at}sohu.com

In this study, CYP2C19 genotypes were tested by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 92 patients with multiple myeloma (MM). Sixty-two patients were treated with thalidomide plus dexamethasone (Thal+Dex) and 30 with thalidomide combined with chemotherapy (Thal+CC). The overall response rate of extensive metabolizers (EMs) was statistically higher than that of poor metabolizers (PMs) (62.6% vs. 33.3%, p<0.05). Similar results were also observed in the Thal+Dex cohort. For the first time, our primary data suggested that the polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in MM.

Key words: thalidomide, multiple myeloma, CYP2C19 genotype, efficacy.




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
Z. Desta, A. Modak, P. D. Nguyen, S. M. Lemler, Y. Kurogi, L. Li, and D. A. Flockhart
Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [13C]Pantoprazole Breath Test
J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 297 - 305.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Jeong, P. D. Nguyen, and Z. Desta
Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A
Antimicrob. Agents Chemother., February 1, 2009; 53(2): 541 - 551.
[Abstract] [Full Text] [PDF]